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Abstract
Background The surgical treatment options for low rectal cancer patients include the Abdominoperineal Resection and 
the sphincter saving Low Anterior Resection. There is growing evidence towards better outcomes for patients being 
treated with a Low Anterior Resection compared to an Abdominoperineal Resection.
Objective The aim of this study was to evaluate the short term and oncological outcomes in low rectal cancer treatment.
Design This is a retrospective cohort study of prospectively collected data.
Setting Rectal cancer patients from a single center in the United Kingdom.
Patients Patients included all low rectal cancer patients (≤ 6 cm from the anal verge) undergoing Low Anterior Resection 
or Abdominoperineal Resection between 2006 and 2016.
Outcome measures To identify differences in postoperative complications and disease free and overall survival.
Results A total of 262 patients were included for analysis (Low Anterior Resection n = 170, Abdominoperineal Resection 
n = 92). Abdominoperineal Resection patients were significantly older (69 versus 66 years), had lower tumours (3 versus 
5 cm), received more neo-adjuvant radiation, had longer hospital stay and more complications (wound infections and 
wound dehiscence). Low Anterior Resections had a significantly higher number of harvested lymph nodes (17 versus 
12) however there was no difference in nodal involvement and R0 resection rate. No significant difference was found for 
recurrence, overall survival and disease free survival.
Limitation Retrospective review of cancer database and single center data.
Conclusion In the treatment of low rectal cancer Abdominoperineal Resection is associated with higher rates of postoper-
ative complications and longer hospital stay compared to the Low Anterior Resection, with similar oncological outcomes.
Keywords Rectal cancer · Surgery · Low anterior resection · Abdominoperineal excision · Cancer recurrence · Survival
1 Introduction
Once the classical paradigm for rectal cancer treatment was; ‘The lower the cancer, the worse its prognosis’. Nowadays 
equivalent oncological outcomes can be achieved for all rectal cancer patients, no matter its height and even with sphinc-
ter preserving options. The first one to describe the APER or Abdomino Perineal Excision of Rectum was Sir W. E. Miles 
in 1908 and for a century this procedure remained the gold standard for the treatment of cancers of the lower rectum. 
This article was presented as an poster presentation on the BASO-The Association for Cancer Surgery Annual Scientific Meeting, 
16th–18th November 2019
 * Jim S. Khan, jim.khan@porthosp.nhs.uk | 1Department of Colorectal Surgery, Portsmouth Hospitals NHS Trust, Southwick Hill, 
Portsmouth PO6 3LY, UK. 2Honorary Associate Professor, School of Health, Education, Medicine and Social Care, Anglia Ruskin University, 
Cambridge, UK.
Vol:.(1234567890)
Clinical Trial Discover Oncology            (2021) 12:7  | https://doi.org/10.1007/s12672-021-00400-1
1 3
Over the last few decades the surgical management of distal rectal cancer has shifted from the traditional APER or Miles 
procedure to low or even ultralow sphincter-preserving anterior resections (LAR, uLAR) [1, 2]. These changes have been 
facilitated by the widespread application of the Total Mesorectal Excision (TME) principle [3], better stapling devices [4], 
recognition of the prognostic importance of an involved circumferential resection margin (CRM) (rather than the distal 
resection margin) and the increasing use of neoadjuvant (chemo)radiotherapy for locally advanced rectal tumours [5, 6].
At present, a safe margin is considered to be a distal mural margin of 1–2 cm [7]. For low rectal tumors a one cm 
distal margin is accepted because distal intramural spread occurs over 1 cm in only 4% to 10% of the cases [8, 9]. This 
knowledge, that a distal margin of 1 cm is considered to be oncologically safe, means that in theory an anastomosis can 
be made at almost any level in the pelvis [6]. Whenever safe margins cannot be achieved, a non-restorative procedure 
is still the treatment of choice. Such is the case when the CRM is involved, with involved Extra Mural Vascular Invasion 
(EMVI), locally advanced lesions with poor response to neoadjuvant therapy and with tumours with external sphincter 
or levator ani muscle invasion [10, 20].
Consequently, sphincter-preserving surgery has now become a priority with many units publishing APER to LAR ratio 
of 1:3 or 1:4 in recent times [11–13]. Furthermore the intersphincteric resection technique offers reconstructive surgery 
in patients with a tumor close to or even in the anal canal without compromising local control and survival.
Radical oncological surgery still remains the main goal of the surgical treatment; however functional outcome, both 
short and long term, must be considered in the balance. Several studies have shown that quality of life in patients treated 
with APER is not inferior to LAR, despite the presence of a permanent colostomy [14]. In case of a low or ultra-low anas-
tomosis the possibility of incontinence or low anterior rectum syndrome (LARS) should also be considered [15]. Thus it 
still remains an argument of debate whether those patients with lower rectal cancer eligible for surgical treatment or 
better treated with the non-restorative APER or sphincter saving LAR.
The aim of this analysis is to compare outcomes between sphincter preserving surgery and APER in a single center 
series of low and ultralow rectal cancer patients, stratified by stage, looking at oncological adequacy of resection, mor-
bidity and short-term results.
2  Patients and methods
Between September 2006 and December 2016, all patients undergoing TME surgery with curative intent for low rectal 
cancer (up to 6 cm from the anal verge) at Queen Alexandra Hospital in Portsmouth (UK) were included in this retrospec-
tive analysis of a prospectively collected database.
All included patients underwent digital rectal examination, sigmoidoscopy and staging with computer tomography 
(CT) of the chest and abdomen and magnetic resonance imaging (MRI) of the pelvis and/or endoanal ultrasound for pre-
operative staging. Patients were offered surgery following a consensus decision by the local Colorectal Multidisciplinary 
Team (cr-MDT) after deciding the need for neoadjuvant chemoradiotherapy (CRT). Long course chemoradiotherapy was 
given to T4 rectal cancers or those with a threatened or involved circumferential resection margin (CRM) on MRI. Curative 
resection was performed either by an open approach or laparoscopically according to the TME principle. Curative being 
defined as no macroscopic cancer left within the abdomen at time of surgery.
The choice between an open and laparoscopic procedure was dependent upon the surgeon’s experience and prefer-
ence for that particular patient. APER or LAR decision was made after detailed consultation with the patient and analysis 
of their preoperative scans and examination findings with regards to the tumor height and distance from the anal verge.
2.1  Data collection and study definitions
The obtained database collected information on demographics, score of the American Society of Anesthesiology (ASA), 
pre-operative clinical stage, neo-adjuvant chemotherapy or radiotherapy, patho-histological data, peri-operative 
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mortality (defined as either in-hospital mortality or death within 30 days of surgery in case of earlier discharge), length 
of hospital stay and post-operative complications using the Clavien-Dindo classification. Survival data was last updated 
on the 30th of June 2017. Disease-free survival was defined as the time from the date of primary treatment (surgery) to 
the date of first recurrence, be it local, systemic or both if they had occurred 6 months apart. Overall survival was defined 
as the time from the date of the primary treatment to the date of death. Patients were divided into 2 groups according 
to the type of procedure, the LAR and the APER group.
2.2  Study outcomes
The primary study outcome was the long-term oncological outcomes (survival, recurrence and disease free survival) 
in patients who had low rectal cancer surgery. Secondary outcome was short term outcomes, including peri-operative 
complications, following rectal surgery.
2.3  Statistical analysis
Statistical analyses was performed using SPSS version 22.0 (SPSS Inc., Chicago, IL, USA). Data was expressed as median 
with inter-quartile ranges. Intergroup comparisons were made using a Mann–Whitney U test for continuous variables or 
chi squared or Fishers exact test for categorical variables. A difference with a p value < 0.05 was considered significant. 
Fig. 1  Flow chart of case 
distribution
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Kaplan–Meier survival plots and the log rank test were used to compare disease-free and overall survival between the 
two groups. Cox regression analysis was performed on all available factors.
3  Results
3.1  Clinicopathologic features
A total of 270 patients were identified to have surgical treatment for low rectal cancer during the study period. Eight 
patients were excluded from further analysis due to incomplete data and lack of follow up. Thus, data from 262 patients 
who underwent a curative surgical TME resection for low rectal cancer were reviewed (Fig. 1). Of these, 170 patients 
underwent LAR and 92 patients were treated with APER. The majority of the resections were performed laparoscopically 
(LAR 82.4%, APER 68.5%), by highly experienced surgeons assisted by a senior registrar/fellow. Patient characteristics and 
treatment details are summarized in Table 1. Overall, the majority of patients was male (72%) with no significant differ-
ence in the male/female distribution between the groups. Patients in the APER group were significantly older, p = 0.040, 
with no significant difference in ASA score and BMI. 
The APER group had a significantly lower tumor height (3 cm in APER vs. 5 cm in LAR, p < 0.001). When comparing the 
distribution of the pre-operative MRI T and N stage, the two groups showed no significant difference. However, significant 
more APER patients had pre-operative radio- and chemotherapy, (p = 0.001 and 0.020 respectively).
Table 1  Patient demographics
Values in italics are statistically significant
Continuous variables expressed as medians and interquartile ranges. Nominal variables expressed as 
absolute numbers with percentages in parenthesis
APR abdominoperienal resection, LAR low anterior resection, BMI body mass index, ASA American Society 
of Anesthesiologists classification, DAV distance from anal verge
Variables LAR APER p value
Number (%) 170 (64.9) 92 (35.1)
Age, years median (interquartile range) 66 (59–75) 69 (62–77) 0.040
Gender M/F 110/60 53/39 0.287
BMI, median (interquartile range) 26 (23–29) 27 (25–31) 0.146
ASA score
 ASA 1 19 (11.2) 4 (4.5) 0.089
 ASA 2 124 (72.9) 62 (69.7) 0.392
 ASA 3 27 (15.9) 23 (25.8) 0.101
DAV, median (interquartile range) 5 (4–6) 3 (2–4) < 0.001
Clinical stage
 I 9 (5.3) 1 (1.1) 0.173
 II 79 (46.5) 36 (39.1) 0.297
 III 62 (36.5) 38 (41.3) 0.506
 IV 7 (4.1) 7 (7.6) 0.257
Pre-operative radiation 41 (24.1) 47 (51.0) 0.001
Neoadjuvant chemotherapy 30 (17.6) 28 (30.4) 0.020
Laparoscopic approach 140 (82.4) 63 (68.5) 0.013
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Table 2  Pathological 
characteristics and long-term 
outcomes
Value in italic is statistically significant
Variables LAR APER p value
Median tumour size, mm (interquartile range) 36 (25–50) 35 (27–40) 0.253
Number of Lymph nodes, median (interquartile range) 17 (12–22) 12 (8–18) < 0.001
Pathological lymph nodes stage
 N0 118 (69.8) 60 (66.7) 0.492
 N1 33 (19.5) 18 (20.0) 1.000
 N2 18 (10.7) 12 (13.3) 0.549
Microscopic tumour infiltration of the margin (R1) 9 (5.3) 11 (12.0) 0.085
Pathological stage
 I 20 (11.8) 5 (5.4) 0.123
 II 65 (38.5) 37 (40.2) 0.791
 III 77 (45.6) 43 (46.7) 0.897
 IV 2 (1.2) 5 (5.4) 0.053
Post-operative chemotherapy 46 (27.1) 20 (21.7) 0.374
Post-operative radiation 2 (1.2) 2 (2.2) 0.614
Local recurrence 7 (4.1) 4 (4.3) 1.000
Distance recurrence 23 (13.5) 18 (19.6) 0.215
Fig. 2  Kaplan–Meier plot 
revealing the survival of LAR 
compared to APR following 
resection for adenocarcinoma. 
No significant difference 
between the two groups 
was demonstrated (log Rank, 
p = 0.514).
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3.2  Oncological and long‑term outcomes
Median tumor size was similar in both groups, p = 0.253. The absolute R1 rate (microscopic tumor infiltration of the mar-
gin) was higher in the APER group, albeit not reaching statistical significance, p = 0.085. The LAR group had a significantly 
higher number of harvested lymph nodes (LN) compared to the APER group, p < 0.001. However, there was no difference 
in lymph node positivity between the two groups, see Table 2. The median survival was 55 months in the APER group 
versus 49 months for the LAR group, although non-significant, p = 0.514 (Fig. 2). 
The overall recurrence rate (local and distant) was 17.6% in the LAR group compared to 23.9% for APER, p = 0.257. There 
was no difference either in the local recurrence or in the distant recurrence rate between the 2 groups (p = 1.000 and 
0.215 respectively). There was also no significant difference in disease-free survival between the two groups (p = 0.455, 
Fig. 3). R1 resection was found to have a negative impact on survival and recurrence disease (Figs. 4 and 5). Furthermore, 
T stage and N stage was found to have a negative impact on patient survival (Figs. 6 and 7).
3.3  Short term outcomes
Patients in the APER groups had a significantly longer length of primary hospital stay compared to LAR patients, 
p < 0.001. Overall, the post-operative complications rate was higher in the APER group compared to the LAR group, 
Fig. 3  Disease free survival 
probability depending on 
type of surgical procedure, log 
Rank = 0.455
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p = 0.028, see Table 3. Amongst both groups only one APER patient died of a myocardial infarction within 30 days of 
the operation. Ten LAR patients had to return to theatre, 6 for an anastomotic leak, 2 cases for abdominal sepsis and 
2 cases for loop ileostomy related complications. In the APER group, again, 10 patients had to return to theatre, but 
for different reasons; 4 patients for stoma related complications, 3 cases for intra-abdominal sepsis and 3 patients 
needed a small bowel resection.
The LAR group had 22 patients who had anastomotic leakage (13%), of which 6 had to return to theatre, 2 had a per-
cutaneous drainage and the remnant patients were treated conservatively. All 22 cases had been given a defunctioning 
loop ileostomy during the first operation.
Major complications (Clavien Dindo grade III and IV) occurred in 49 patients of the entire cohort (19%), but a major 
complication did not have a negative impact on long term survival, Fig. 8.
During last follow up, 99/170 (58.2%) in the LAR group had their loop ileostomy reversed. 19 cases (14%) from the 
APER group had developed a symptomatic parastomal hernia.
Fig. 4  Cumulative survival 
for patients undergoing a 
curative resection for low 
rectal cancer comparing 
patients with R0 resection to 
patients with R1 resection, log 
Rank = 0.023
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4  Discussion
Rectal cancer patients still often experience surgical complications, regardless of the important progress made 
so far within both techniques and perioperative management. In this study, considerable short-term survival 
benefits in favor of the LAR group were achieved. Overall, post-operative complication rate was higher in APER 
group which was mainly caused by the high incidence of perineal wound failure and they had a significantly 
longer length of primary hospital stay compared to LAR patient (median 12 vs. 7 days, Table 3). The anastomotic 
leak rate in LAR was 13%.
The most common complication of APER is perineal wound failure and can be as high as 30% [16]. Anastomotic 
leakage is considered to be the major complication of restorative LAR with studies reporting an average leakage rate of 
11–12% in high volume centers following rectal cancer surgery which is comparable with our AL rate [17]. However, it is 
demonstrated that the postoperative complications such as pelvic sepsis, urinary and sexual dysfunction, are higher in 
the APER group than in the LAR group [17].
Fig. 5  Disease free survival 
probability depending on 
R1 margin resection, log 
Rank < 0.001
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In this study we achieved a sphincter-preservation rate of 50% in low rectal cancers and believe that this should 
remain a priority since only an average of 20% of patients in the APER group is satisfied with having a permanent 
colostomy [14]. In fact, patients undergoing APER have restrictions in their postoperative Quality of Life, such as 
body image, which can lead to altered social life [14, 15]. However, in elderly patients with more distal, more locally 
advanced disease that requires radiotherapy, as our data show, APER performed with appropriate skill, remains a 
safe option.
For the oncological outcome, the achievement of technical excellence in TME surgery at our center is reflected in 
the low local recurrence rates in both surgical groups when compared to other studies. For instance, a meta-analysis 
Fig. 6  Cumulative survival for 
patients undergoing a cura-
tive resection for low rectal 
cancer according to T stage, 
log Rank = 0.001
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from 2015 suggested that compared to APER, LAR has better 5-year survival rates, lower CRM rates, less local recur-
rence and less complications [18].
CRM involvement is a recognized prognostic factor for local recurrence. Patients who undergo APER have shown to 
have a higher incidence of CRM involvement [18, 19] and has, unfortunately, not diminished with TME. The distance 
from the anal verge is related to the completeness of TME, because of the greater challenge of performing a perfect 
resection with adequate margins low down in the pelvis. TME surgery cannot always be carried out down to the 
levator muscles plane in APER because of the presence of a large tumor. CRM involvement in the APER specimens is 
often related to the removal of less tissue at the level of the tumor because of a different resection plane. However, 
the lower cancers elected for APER may be associated with a different pattern of lymphatic spread, which is not 
included in the tumor package harvested with TME [18, 19].
Fig. 7  Cumulative survival for 
patients undergoing a cura-
tive resection for low rectal 
cancer comparing patients 
with N0, N1 and N2 stage, log 
Rank = 0.001
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We believe that in selected low rectal cancer patients, APER is a better option than LAR. In current literature, despite 
rigorous methodology, the intrinsic limitation/bias of the studies should be considered, and conclusions interpreted 
with caution. The APER tumors are usually closer to the anal verge and more bulky. Although the patients in the LAR 
and APER groups are comparable in terms of age, tumor stage, and neoadjuvant treatment and the distribution of 
tumor stage, however, it would not be possible to eliminate this bias as bigger tumors would tend to undergo a Miles 
procedure, as sphincter saving would not be attempted. The extent of tumor spread in itself is therefore unlikely to 
account for the increased surgical margin involvement, consequent local recurrence and lower survival in the APR 
group.
Table 3  Short-term post 
operative outcomes
Values in italics are statistically significant
Nominal variables expressed as absolute numbers with percentage in parenthesis
APER abdominoperineal resection, LAR low anterior resection
Variables LAR APER p value
Number (%) 170 (64.9) 92 (35.1)
Overall complications 77 (45.3) 55 (59.8) 0.028
Clavien-Dindo classification
 I 21 (27.2) 4 (7.3)
 II 31 (40.3) 26 (47.3)
 IIIa 12 (15.6) 11 (20.0)
 IIIb 12 (15.6) 10 (18.2)
 IV 1 (1.3) 3 (5.4)
 V 0 (0.0) 1 (1.8)
Urinary infection 16 (9.4) 5 (5.4) 0.343
Wound infection 17 (10.0) 25 (27.2) 0.001
Wound dehiscence 0 (0.0) 9 (9.8) < 0.001
Intra-abdominal or pelvic collection 13 (7.6) 8 (8.7) 0.813
Percutaneous drainage 5 (2.9) 2 (2.2) 1.000
Anastomotic leak 22 (12.9) NA NA
High stoma out-put 13 (7.6) NA NA
Post-operative ileus 9 (5.3) 2 (2.2) 0.338
Post-operative bleeding 5 (2.9) 4 (4.3) 0.724
Re-operation 10 (5.9) 10 (10.9) 0.153
Readmission 25 (14.7) 16 (17.4) 0.595
Peri-operative mortality 0 (0.0) 1 (1.1) 0.351
Hospital stay, days, median (interquartile range) 7 (5–13) 12 (8–19) < 0.001
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5  Conclusion
In conclusion, our single centre findings show that LAR has a similar oncological outcome for low rectal cancer when 
compared to APER. However, APER is associated with a higher rate of post-operative complications and longer hospital 
stay. A tailored approach suited to the individual patients needs supported by the multidisciplinary team should be 
recommended. 
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Fig. 8  Cumulative survival for 
patients undergoing a cura-
tive resection for low rectal 
cancer comparing patients 
who had a major complica-
tion, log Rank = 0.442. 0 = no 
complication, 1 = major 
complication (Clavien Dindo 
Grade III/ IV)
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